Karen Reckamp, MD

Case Overview: 68-Year-Old Woman with ALK+ NSCLC

Treatment Options in ALK+ NSCLC

FDA Approval of Frontline Brigatinib in ALK+ mNSCLC

ALTA-1L Trial: Brigatinib

Sequencing ALK Inhibitors

ALK+ mNSCLC: Advancements Made and What’s Next

Case: A 68-Year-Old Woman with ALK+ Non–Small Cell Lung Cancer

A 68-year-old woman presented with fatigue, wheezing and decreased appetite

PE: wheezing on auscultation; ECOS PS 1
 

Chest x-ray showed a left lower lobe mass

Chest/abdomen/pelvic CT scan confirmed a 6.8-cm left lower lobe lung mass and a suspicious liver lesion

PET scan showed activity in the left lower lobe mass and liver

MRI of the brain showed several subcentimeter lesions without edema

Bronchoscopy with transbronchial biopsy of the left lower lobe mass confirmed lung adenocarcinoma

Patient was started on brigatinib 90 mg qDay for 7 days; well tolerated; dose was increased to 180 mg qDay

Videos

Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.

A 68-Year-Old Woman with ALK+ Non–Small Cell Lung Cancer

Karen Reckamp, MD, co-director of the Thoracic Oncology Program at the City of Hope Comprehensive Cancer Center, discusses combinations with immunotherapy in lung cancer at the International Lung Cancer Congress. She says this is a very hot topic in the field right now.

The first combination she brought up in her talk was ipilimumab (Yervoy) plus nivolumab (Opdivo). According to data presented earlier this year at the annual AACR meeting, this combination showed significant progression-free survival benefit over chemotherapy in a subset of patients with high tumor mutational burden (TMB).

Another hot topic in the field included the combination of MET inhibitors with immunotherapy. After seeing positive results for this combination in renal cell carcinoma, a number of ongoing trials are now looking at this combination in lung cancer, including the combination of ipilimumab, nivolumab, and the MET inhibitor cabozantinib (Cabometyx).

Another area that has been looked at is the combination of immunotherapy plus targeted therapies, such as osimertinib (Tagrisso). This agent has been established as a well-tolerated and efficacious drug, but the results in combination with an immunotherapy were not as fantastic as hoped, Reckamp says.

Crizotinib (Xalkori) is another agent that works well for

Karen Reckamp, MD | Authors

Articles

A 68-Year-Old Woman with ALK+ Non–Small Cell Lung Cancer

Hot Topics With Immunotherapy in Lung Cancer